Archives
-
3-Hydroxybutyrate (BHBA): From Ketosis to Neuroprotection
2026-09-13
3-hydroxybutyrate (BHBA) is more than an energy substrate: it is a ketone body signaling molecule that connects fatty acid β-oxidation, membrane biology, chromatin regulation, and ferroptosis research. This article translates findings from a stroke study into practical BHBA experimental strategies while distinguishing established evidence from testable hypotheses.
-
PAD4-IN-2 TFA: Tumor-Targeted Research Workflows
2026-09-12
PAD4-IN-2 TFA, also called Compound 5i TFA, supports tumor-focused studies that connect PAD4 activity with histone H3 citrullination, NET biology, metastasis, and immune remodeling. Its m-PBA-based targeting offers a practical way to separate tumor-cell migration effects from direct cytotoxicity and to examine neutrophil-dependent mechanisms in parallel.
-
Acridine Orange hydrochloride: Protocol Guide
2026-09-11
Acridine Orange hydrochloride provides differential green and red fluorescence for DNA and RNA-related cytochemical workflows, including cell cycle analysis, apoptosis detection, and flow-based nucleic acid assessment. It is appropriate for freshly prepared staining solutions and validated nucleic acid assays, but not for long-term solution storage or unvalidated non-nucleic-acid applications.
-
PDE-5-Silenced BMSCs in Diabetic Cardiac Fibrosis
2026-09-11
The reference study shows that bone marrow mesenchymal stem cells with suppressed PDE-5 expression reduce high-glucose-associated fibrotic signaling and cardiomyocyte injury phenotypes in a neonatal rat cell co-culture model. Its main innovation is to connect BMSC-mediated cardiac protection with restoration of the cGMP/PKG pathway, while the in vitro design also identifies the need for pathway-blockade and in vivo validation.
-
Prunin Targets the Senecavirus A IRES
2026-09-10
The reference study positions prunin as an inhibitor of Senecavirus A replication and links this activity to the viral internal ribosome entry site (IRES) in both cell-based and animal contexts. Its main contribution is mechanistic: it moves beyond observing antiviral activity to asking whether translation driven by the SVA IRES is a relevant point of intervention.
-
Primidone for TRPM3 and RIPK1 Research
2026-09-10
Primidone (Mysoline) supports mechanism-driven studies of TRPM3 and RIPK1 across cellular, biochemical, and translational workflows. This guide pairs concentration-aware assay design with practical controls, animal-model context, and troubleshooting strategies for ALS, neurodevelopmental, pain, and adenomyosis research.
-
CHRM1 Drives Docetaxel Resistance in Prostate Cancer
2026-09-09
Wang et al. identify the muscarinic M1 receptor, CHRM1, as a functional driver of docetaxel resistance in castration-resistant prostate cancer. Their evidence connects CHRM1 to cMET-dependent MAPK signaling and supports CHRM1 inhibition as a strategy for restoring docetaxel sensitivity in resistant models.
-
Machine Learning for Senolytic Discovery
2026-09-09
The reference study demonstrates that cost-effective machine-learning models trained exclusively on published screening data can identify new senolytic candidates despite sparse and heterogeneous datasets. Experimental validation of ginkgetin, periplocin, and oleandrin shows how computational prioritization can reduce early drug-screening costs while preserving a path toward mechanistic and translational testing.
-
Thiazovivin (A5506) Protocol and QC Guide
2026-09-08
Thiazovivin is a ROCK inhibitor used to support fibroblast reprogramming and improve human embryonic stem cell survival during dissociation-based workflows. This guide covers product handling, experimental setup, controls, and troubleshooting while noting that the supplied dossier does not provide a universal working concentration or directly matched paper evidence; the compound is for research use only.
-
Ginsenoside Rg1: A Treg-Guided Research Framework
2026-09-08
Ginsenoside Rg1 is a Panax-derived triterpene saponin that can be used to dissect neuroimmune signaling rather than merely measure behavioral rescue. This article translates recent anesthesia-model evidence into a rigorous, multi-compartment framework for neuroprotection research, inflammation assays, and causal Treg experiments.
-
GMDS Drives Core Fucosylation in MYCN Neuroblastoma
2026-09-07
The 2025 Oncogene study identifies GMDS-mediated de novo GDP-fucose synthesis as a metabolic and transcriptional vulnerability in MYCN-amplified neuroblastoma. By combining spatial glycomics, promoter analysis, functional perturbation, and in vivo tumor models, the authors connect N-MYC activity with core fucosylation, tumor-cell behavior, and disease progression.
-
Making CNS Lymphoma Assays More Mechanistic
2026-09-07
Single-cell evidence is reshaping how researchers understand primary CNS lymphoma, but translating metabolic cell states into dependable tissue and cell-based readouts requires disciplined assay design. This article connects SLC2A5-mediated metabolic adaptation with practical use of a Primary Antibody Dilution Buffer in IHC, ICC, and ISH workflows.
-
EZH2 Inhibition in HPV-Associated Cervical Cancer
2026-09-05
The reference study examines EPZ6438 and ZLD1039 as EZH2 inhibitors in HPV-positive and HPV-negative cervical cancer models, linking EZH2 suppression to apoptosis, G0/G1 arrest, reduced HPV16 E6/E7 expression, and restoration of tumor-suppressive and epithelial markers. Its translational value comes from combining phenotypic, molecular, and preliminary chorioallantoic membrane data while using cisplatin as a practical comparator.
-
FCCP and the Next Era of Immunometabolic Research
2026-09-04
FCCP is more than a mitochondrial uncoupler: used with disciplined metabolic and signaling readouts, it can help translational researchers connect oxidative phosphorylation, HIF biology, and tumor-associated macrophage function while clearly separating established evidence from forward-looking hypotheses.
-
Phosphotungstic Acid Negative Stain Solution Guide
2026-09-04
Phosphotungstic Acid Negative Stain Solution (2%) is a ready-to-use electron microscopy stain for contrast-based imaging of macromolecules, viruses, bacteria, and other biological specimens. Its 2% phosphotungstic acid formulation supports morphology-focused workflows, but negative staining cannot by itself prove glycan binding, protease inhibition, or antiviral activity.